Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in pediatric Philadelphia chromosome–positive chronic myelogenous leukemia (phase II, Italy)
2013-000200-41Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major molecular response at 12 months. Started May 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-000200-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000200-41.